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Abstract
Aims: This study aims to assess vaginal wall angioarchitecture and function in
women with vulvovaginal atrophy (VVA) and determine the effect of topical
estrogen on the vaginal microcirculation.
Materials and Methods: In this prospective observational study, incident dark
field imaging was used to assess the vaginal microcirculation. In patients with
VVA, measurements were performed before and after treatment with topical
estrogen and compared to measurements performed in women without VVA.
Vaginal angioarchitecture was studied by assessing microcirculatory architec-
ture and capillary tortuosity scores at four regions of the vaginal wall. In
addition, the capillary density and microvascular flow index (MFI) were
obtained.
Results: Seventeen women were included in this study. Of these, eight women
were diagnosed with VVA and nine women were considered healthy controls.
Significant differences were observed between groups with regard to micro-
circulatory architecture scores. The architecture of the microvasculature in
women with VVA was characterized by the appearance of a vascular network
without capillary loops, whereas an array of capillary loops was predominantly
seen in women without VVA. After estrogen treatment, no difference in
architecture scores between patients and healthy controls was observed.
Capillary tortuosity, capillary density, and MFI were similar in both groups
before and after estrogen treatment.
Conclusions: The architecture of vaginal microvasculature is altered in
patients with VVA. In case of similar vascular architecture, capillary tortuosity
and density seem to be comparable. Treatment with topical estrogen results in
restoration of the angioarchitecture.
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1 | INTRODUCTION
Vulvovaginal atrophy (VVA) is a common condition
in postmenopausal women. The prevalence of VVA
dramatically increases during the menopausal transi-
tion, whereas most postmenopausal women suffer from
their associated symptoms.1 As a consequence of
vaginal discomfort and pain, VVA has a significant
impact on daily activity, sexual function, and overall
quality of life.2 VVA is characterized by dryness,
erythema, and petechiae of the vaginal wall and is
associated with a thin and pale epithelium resulting
from low estrogen levels specific for menopause.3
It is well known that vaginal estrogen therapy is
efficacious in treating symptoms of VVA.4 Therapy with
estrogen thickens the epithelium, decreases vaginal
dryness, and seems to optimize vaginal blood flow.5
Since sufficient estrogen levels support the proliferation
of vascular and nonvascular smooth muscle cells in the
subepithelial layers of the vagina, estrogen is considered
to affect vaginal wall perfusion and oxygenation.6 The
actual perfusion of vaginal tissue and the exchange of
nutrients and gases (ie, O2 and CO2) between the
intravascular space and the vaginal tissue occurs at the
level of the microcirculation (ie, in the capillaries).
Therefore, the capillary vessel bed should be considered
essential for a healthy vaginal environment.7
To what extent VVA affects the vaginal microcircula-
tion is not well objectified, and it is unknown whether
treatment with vaginal estrogen results in changes to the
microcirculation. Therefore, assessment of the vaginal
microcirculation before and after estrogen treatment can
improve understanding of the working mechanism of
vaginal estrogen therapy.
With the use of handheld microscopy imaging, human
microcirculation can be assessed in great detail.8 This
imaging technique has been used to assess the micro-
circulatory status of different human organ surfaces.9-11
Incident dark field (IDF) imaging was used to assess the
vaginal microcirculation in healthy subjects12 and in
patients with prolapse.13 IDF imaging uses high‐bright-
ness green LEDs. The emitted green light is absorbed by
hemoglobin in the red blood cell, allowing visualization
of the microcirculation.8 In another study, the same
authors demonstrated that topical estrogen therapy
results in thickening of the epithelial layer and that it
could be assessed noninvasively with IDF imaging.14
It is hypothesized that topical estrogen therapy has an
effect on the vaginal microcirculation in women with VVA:
therapy possibly changes the angioarchitecture and quan-
tity of capillaries, thereby improving the diffusion and
convection of oxygen to the vaginal tissue. To test these
hypotheses, this study compares the microcirculation
between women with and without VVA and objectifies
the effects of topical estrogen on the vaginal microcircu-
lation.
2 | MATERIALS AND METHODS
2.1 | Participants and setting
We performed a prospective, single‐center observational
study at the outpatient clinic of the Department of
Obstetrics and Gynecology of a University Medical Center.
Women enrolled in this study received a full explanation of
the study guidelines and procedures. Written informed
consent was obtained from each participant.
Postmenopausal women that were meant to receive
treatment with topical estrogen for VVA were recruited.
Synapause‐E3 ovules 0.5 mg were self‐administered at
home daily for 2 weeks followed by two times per week
for at least 4 consecutive weeks. Medical history was
obtained and women with cardiovascular (eg, angina
pectoris, uncontrolled hypertension), inflammatory (eg,
rheumatoid arthritis, eczema), other systemic illness (eg,
inadequately controlled [non‐] insulin‐dependent dia-
betes mellitus) or those taking medication (eg, antic-
oagulants, anti‐inflammatory, or immunosuppressive
agents) that could affect the microcirculation were
excluded from participation. Women with a history of
vaginal surgery were also excluded, because of its
uncertainty to what extent vaginal surgery affects the
vaginal microcirculation.
VVA was diagnosed based on the following three
characteristics: (1) the presence of a most bothersome
symptom involving at least one of the following symptoms:
vaginal dryness, vaginal itching or irritation, dyspareu-
nia;15 (2) the presence of one or more of the following signs
at physical examination: vaginal wall pallor and petechiae,
friability of the vaginal wall (defined as any bleeding
occurring during examination), conization (markedly de-
creased elasticity), or the absence of rugae;16 and (3) a
vaginal pH of at least 5.5.17 pH was measured using a pH
strip with a pH range of 3.8 to 5.5 with intervals of 0.3
(Dosatest; Prolabo; VWR International, Leuven, Belgium).
The control group consisted of women aged 40 years
or older with no signs or symptoms of VVA, attending the
outpatient clinic because of bothersome pelvic floor
symptoms and no previous history of vaginal surgery or
use of topical estrogen.
2.2 | Microcirculation imaging
The vaginal microcirculatory assessment was performed
using IDF imaging (Cytocam; Braedius Medical, Huizen,
the Netherlands). This technique has been described in
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detail previously.8 In summary, IDF imaging contains
high‐brightness LEDs with a very short illumination
pulse time of 2 ms. Greenlight is absorbed by hemoglobin
in the red blood cell, allowing visualization of the
microcirculation. The device is a lightweight (120 g)
and pen‐like instrument (length 220mm, diameter
23 mm). The combination of factor 4 optical magnifica-
tion and a large sensor image area provides a field of view
of 1.55 × 1.16 mm, which equates 1.80 mm2. The optical
system provides an optical resolution of more than
300 lines/mm. The camera is connected to a device
controller on a computer that is used for image storage
and off‐line analysis.
2.3 | Microcirculatory examination and
data acquisition procedure
Participants were examined in a gynecological chair in a
stable 45°° semi‐reclined position in a room kept at a
constant temperature. An experienced researcher, skilled
in measuring the vaginal microcirculation, conducted all
measurements. The CytoCam was placed into contact
with the vaginal wall at exactly 3 cm above the hymen.
The pressure of the device on the vaginal wall was
avoided to prevent pressure‐induced flow‐artifacts, and
the CytoCam was adjusted for optimal focus and contrast.
The anterior, posterior, and lateral vaginal walls were
measured to calculate a general vaginal measurement.
All measurements were stored as video clips which were
directly saved as digital AVI‐DV files to a hard drive.
Videos were blinded and anonymized so that the
observer was not aware of the intervention and
time point. Image assessment was performed in a random
fashion.
2.4 | Quality score assessment
Each video clip was assessed through a scoring system
based on six parameters (illumination, focus, content,
stability, pressure, duration); failure to meet a parameter
disqualified a video clip from the analysis.18
2.5 | Tissue angioarchitecture
This scoring system allows for classification of subepithe-
lial vascular patterns.12,13 Microvascular architecture
scores from each measurement site were examined and
systematically classified with a score of 1, 2, or 3. Score 1,
defines the appearance of an array of capillary loops; in
score 2, both capillary loops and vascular network are
visible, and score 3, is defined by the appearance of a
vascular network with a complete absence of capillary
loops. The overall microcirculatory architecture score per
anatomical region per subject was determined by
selecting the most frequently observed architecture score
in the available frames.
2.6 | Capillary tortuosity score
Additional description of the microvasculature is the
capillary tortuosity (number of twists per capillary).
Capillary tortuosity is a microvascular feature which has
previously been associated with chronic disease.19 A frame
was judged suitable for assessment if capillary loops and the
presence or absence of twists could be clearly identified.
Capillary tortuosity was classified as score 0: no twists (or
pinhead capillaries) to 4: four or more twists.12 The overall
tortuosity score per anatomical region per subject was
determined by selecting the most frequently observed
tortuosity score in the available frames.
2.7 | Assessment of capillary density
Assessment of the capillary density was performed by
counting the number of capillary loops per visual field from
the video clips from each of the four anatomical regions. The
capillary density obtained from one isolated image frame
expressed as the median number of capillary loops per
square millimeter (cpll/mm2), was used to quantify the
vaginal microcirculation at each of the associated vaginal
wall regions. Each image frame provides a field of view of
1.55× 1.16mm, which equates 1.80mm2. Capillary density
was assessed in each frame where capillary loops could be
clearly identified and calculated by counting the number of
capillary loops per field of view area and divided by 1.80 to
obtain a unit cpll/mm2.
2.8 | Microvascular flow index
Microvascular flow characteristics were assessed using the
microvascular flow index (MFI). This score was previously
developed and tested for reproducibility by Boerma et al20
and is based on the determination of the predominant type
of flow in four quadrants. Flow is characterized as absent
(0), intermittent (1), sluggish (2), or continuous (normal)
(3). The MFI score per region was calculated by averaging
the MFI scores over four quadrants per frame per region.
2.9 | Statistical analysis
The aim of the analysis was (1) to compare microcirculatory
parameters between women with and without VVA, and (2)
to compare microcirculatory parameters in women before
and after treatment with topical estrogen. Significant
differences were found in a previous study on this topic
using a small sample size,14 therefore, this study used the
1300 | DIEDRICH ET AL.
same sample size. Descriptive statistics were used to present
the demographic variables. Non‐normally distributed data
are presented as medians with interquartile ranges. Normally
distributed data are presented as means and standard
deviations. For differences between the two groups in tissue
microcirculatory architecture and capillary tortuosity scores,
the χ2 test was used. Capillary density was compared
between groups using the Mann–Whitney U test for non‐
normal distribution. A two‐sided P<0.05 was considered
statistically significant. All data were analyzed using SPSS,
version 23.0 for Windows (IBM Corp, Armonk, NY).
2.10 | Ethical approval
This study was approved by the Medical Ethics Committee
of the Amsterdam UMC.
3 | RESULTS
3.1 | Participants
A total of 17 women were included in this study. Of these
women, 8 women were diagnosed with VVA (median age
65 years; interquartile range [IQR] 56‐74 years) and
9 women were considered healthy controls (median age
49 years; IQR 45‐59). Women in both groups were
comparable with regard to parity (VVA median 2 [range
1‐3] vs without VVA 2 [range 1‐3]). In the control group,
women had no signs or symptoms of VVA and visited the
clinic because of an abnormal pap smear (n= 2), urinary
incontinence (n= 4), recurrent urinary tract infections
(n= 1), and/or pelvic organ prolapse (n= 4). A few patients
did not undergo the second measurement in the VVA
group (n= 1) and control group (n= 2).
3.2 | Physical examination
Before treatment, there was a statistically significant
difference between the median vaginal pH in the VVA
and healthy control group (5.5 vs 5.1, respectively;
P< 0.01). pH of the VVA group did change from 5.5 to
5.0, however, this results was not significant (P= 0.07).
No significant difference was found in the control group
over time (5.1 vs 5.2; P= 0.32). Clinical signs of VVA (eg,
vaginal wall pallor and petechiae, friability of the vaginal
wall, conization, or the absence of rugae) improved in six
out of seven patients in the VVA group.
3.3 | Tissue angioarchitecture
Vaginal angioarchitecture differed significantly between
women with and without VVA (Table 1). In women with
TABLE 1 Microcirculatory architecture scores of patients and controls at both time points
Microcirculatory architecture score at baseline (t= 0)
Microcirculatory architecture score, 2nd
measurement (t= 1)
Patients (n = 8) Control (n = 9) P* Patients (n = 7) Control (n = 7) P*
Anterior 0.02 0.30
Score 1 2 (25) 8 (89) 6 (86) 7 (100)
Score 2 4 (50) 0 (0) 1 (14) 0 (0)
Score 3 2 (25) 1 (11) 0 (0) 0 (0)
Left 0.02 0.84
Score 1 2 (25) 8 (89) 4 (57) 3 (43)
Score 2 2 (25) 1 (11) 2 (29) 3 (43)
Score 3 4 (50) 0 (0) 1 (14) 1 (14)
Posterior 0.07 0.58
Score 1 2 (25) 7 (78) 5 (71) 4 (57)
Score 2 4 (50) 2 (22) 2 (29) 3 (43)
Score 3 2 (25) 0 (0) 0 (0) 0 (0)
Right 0.08 0.08
Score 1 2 (25) 6 (67) 2 (33)** 6 (86)
Score 2 3 (37.5) 3 (33) 3 (50) 0 (0)
Score 3 3 (37.5) 0 (0) 1 (17) 1 (14)
Score 1: appearance of an array of capillary loops; Score 2: both capillary loops and vascular network are visible, and Score 3: appearance of a vascular network,
absence of capillary loops. Values are number (percentage).
Bold values <0.05 are considered statistically significant.
*The χ2 test.
**Only six measurements, clips from one patient were extracted because of a low‐quality score.
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VVA, a score 3 was predominantly seen (Figure 1A),
whereas a score 1 architecture was predominantly seen in
healthy controls (Figure 1B). After treatment with estrogen,
a significant change in architecture score was observed,
resulting in angioarchitecture that was comparable to the
angioarchitecture y seen in the control group (Table 1).
3.4 | Capillary tortuosity score
Capillary tortuosity score was assessed in all frames
except for frames with hardly identifiable capillary loops
and mainly the appearance of the underlying vascular
network (architecture score 3). Capillary tortuosity scores
were similar in both groups before and after treatment
with estrogen. Score 1 and 2, illustrating one or two
capillary loop twists subsequently, were most frequently
found (Tables S1 and S2).
3.5 | Assessment of capillary density
Assessment of capillary density was performed on all frames
including an array of capillary looks, architecture score 1.
Capillary density was similar during the first measurement
for all anatomical regions (anterior vaginal wall VVA 16.2
cpll/mm2 [13.2‐17.3] vs control 12.8 cpll/mm2 [11.4‐15.1];
P=0.20). Also after treatment with estrogen, no significant
differences were seen in capillary density between the two
sites for all anatomical regions (anterior vaginal wall VVA
12.4 cpll/mm2 [11.4‐15.8] vs control 13.3cpll/mm2 [12.1‐17.2];
P=0.93) (Table S1).
3.6 | Microvascular flow index
All patients and controls had at both time point an MFI
score of 3.0 [confidence interval, 3.0 to 3.0] corresponding to
continuous flow.
4 | DISCUSSION
This is the first study to report on the effects of VVA and
topical estrogen therapy on the architecture of vaginal
microcirculation using an in vivo noninvasive technique.
Our results demonstrate that in women with VVA,
angioarchitecture in the subepithelial layer of the vagina
is altered. Treatment with estrogen has a distinct effect
on the architecture of the vaginal microcirculation and
has the potential to reverse the vascular alterations
observed in VVA to normal angioarchitecture as observed
in women without VVA.
Four layers characterize vaginal tissue: the epithe-
lium, the lamina propria, a muscularis layer, and the
adventitia.21 The epithelial layer is not directly vascular-
ized but receives nutrients and oxygen via capillary loops
and diffusion from the vascular network beneath, located
in the lamina propria. In this case, IDF imaging shows a
thick epithelial layer and a lamina propria with a pattern
of capillary loops (architecture score 1), without a visible
background of the vascular network. However, in women
with VVA, a significantly higher degree of architecture
scores 2 and 3 were observed at baseline: a vascular
network without capillary loops. After treatment with
estrogen, a score 1 architecture was also predominant in
the VVA group. This is graphically illustrated in Figure 2.
It is unknown why a hypoestrogenic state alters
vaginal vasculature. The altered angioarchitecture could
be an effect of a thinner epithelium and loss of crypts, for
which delivery of oxygen and nutrients through capillary
loops is no longer necessary. However, since estrogen
regulates the growth and function of vascular and
nonvascular smooth muscle cells in the subepithelial
layers in the vagina,22 another explanation could be that
the lack of estrogen has a direct negative effect on the
vaginal vasculature. The absence of capillary loops in the
vaginal microcirculation can have clinical consequences.
Capillary loops are also present in the skin, where this
form of vascularization is considered to be better resistant
against trauma, and protects the larger vessel bed
beneath and facilitates thermal regulation by constriction
and dilation of the capillary loops.23 Similar features can
possibly be attributed to the vaginal epithelium with
capillary loops. Among other functions, capillary loops
could play a role in vaginal lubrication under the
mediation of endothelial nitric oxide synthases and a
FIGURE 1 Incident dark‐field
illumination images of the vaginal
microcirculation. A, Architecture
score 3 (appearance of the vascular
network without capillary loops) seen in
vulvovaginal atrophy. B, Architecture
score 1 (appearance of an array of
capillary loops) seen in healthy controls
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hypoestrogenic state.24 Hypothetically, a microvascula-
ture without capillary loops can also cause vaginal
dryness with itching or irritation as result.
Analysis of the capillary density and microvascular
flow showed no statistically significant differences
between patients and controls, neither before nor after
treatment. Capillary density and flow are both para-
meters for tissue perfusion, which depends on the
number and distribution of the capillaries in combination
with blood viscosity and pressure. The two main
hemodynamic principles that determine oxygen supply
to tissue are convection and diffusion. Convection is
quantified by flow, whilst diffusion is normally quantified
by the density of the perfused microvessels. However, it
can be argued if this also applies to the vagina, where
angioarchitecture might be a more important factor
facilitating oxygen diffusion rather than a high density
of the microvessels. In addition, we analyzed capillary
tortuosity. This morphologic characteristic has been
associated with pathology such as diabetes, but its
biological explanation is currently unknown.19 We
observed no differences in tortuosity scores between
groups, and these scores were comparable to nondiabetic
patients. Future research should be focused on the
relationship between the qualitative aspect of microves-
sels and their ability to deliver oxygen to the cells.
Potential limitations of this study need to be
addressed. First of all, although the CytoCam has the
largest field of view among existing handheld video
microscopes, its field of view is still relatively small
(1.55 × 1.16 mm). Therefore, it can be debated if the
imaged area is an adequate representation of the entire
vaginal wall or vaginal canal. In a future study, it could
be interesting to more extensively map microvascular
changes throughout the vagina in patients with VVA. A
thorough mapping could also provide information on the
course of VVA and how and when it affects the
microcirculation in different parts of the vagina.
Secondly, the assessment of the vaginal vessel density is
challenging with analysis programs that are currently
available (eg, automated vascular analysis). Such pro-
grams can calculate total vessel densities, but not when
capillary loops are present. Therefore, it is not possible to
use these programs for analysis of vaginal images, and it
is impossible to compare density parameters between
different architecture scores. In this study, we calculated
capillary density by manually counting loops per field of
view in architecture score 1 and 2 dominant tissue (as
was validated by Weber et al12). Unfortunately, with this
method, capillary density cannot be calculated in
architecture score 2 and 3 tissue, since capillary loops
were limited to absent. This limits the report on vaginal
capillary density. Thirdly, since this is the first study on
this topic, no data from previous studies were available.
Consequently, we could not perform a power calculation.
Therefore, we should be cautious to generalize these
findings, which were observed in a relatively small
patient population.
5 | CONCLUSIONS
The architecture of the vaginal microvasculature is
altered in women with VVA. In case of similar vascular
architecture, capillary tortuosity, and density seem to be
comparable. Treatment with topical estrogen results in
restoration of the vaginal angioarchitecture. From other
studies we have learned that vaginal estrogen therapy
improves the quality of the vaginal epithelium, and
apparently, qualitative aspects of the microcirculation
play an important role as well. Future research should be
focused on how to preserve the quality of the micro-
circulation in women who are exposed to events like
aging, vaginal delivery, and pelvic floor surgery.
FIGURE 2 A, Illustration of healthy
vaginal tissue with a dense epithelial layer
including crypts and capillary loops
originating from the vascular network
(architecture score 1). B, Illustration of
atrophic vaginal tissue, a thin layer of
epithelium with loss of crypts and
capillary loops, residual vascular network
visible (architecture score 3)
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